Search Results - "NAICHI LIU"

A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control by BHASKAR, Vinay, GOLDFINE, Ira D, NARASIMHA, Ajay J, LEVY, Raphael, WEBSTER, Lynn, WIJESURIYA, Sujeewa D, NAICHI LIU, XIAORONG WU, CHEMLA-VOGEL, David, TRAN, Catarina, LEE, Steve R, WONG, Steve, BEDINGER, Daniel H, WILCOCK, Diane, WHITE, Mark L, CORBIN, John A, LAU, Angela, KUAN, Hua F, GROSS, Lisa M, HANDA, Masahisa, MADDUX, Betty A, WATSON, Susan R, ZHU, Shirley

“…Many patients with diabetes mellitus (both type 1 and type 2) require therapy to maintain normal fasting glucose levels. To develop a novel treatment for these…”
Get full text

Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity by Corbin, John A, Bhaskar, Vinay, Goldfine, Ira D, Bedinger, Daniel H, Lau, Angela, Michelson, Kristen, Gross, Lisa M, Maddux, Betty A, Kuan, Hua F, Tran, Catarina, Lao, Llewelyn, Handa, Masahisa, Watson, Susan R, Narasimha, Ajay J, Zhu, Shirley, Levy, Raphael, Webster, Lynn, Wijesuriya, Sujeewa D, Liu, Naichi, Wu, Xiaorong, Chemla-Vogel, David, Lee, Steve R, Wong, Steve, Wilcock, Diane, White, Mark L

“…Previously we reported studies of XMetA, an agonist antibody to the insulin receptor (INSR). We have now utilized phage display to identify XMetS, a novel…”
Get full text

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity by Roell, Marina K., Issafras, Hassan, Bauer, Robert J., Michelson, Kristen S., Mendoza, Nerissa, Vanegas, Sandra I., Gross, Lisa M., Larsen, Paul D., Bedinger, Daniel H., Bohmann, David J., Nonet, Genevieve H., Liu, Naichi, Lee, Steve R., Handa, Masahisa, Kantak, Seema S., Horwitz, Arnold H., Hunter, John J., Owyang, Alexander M., Mirza, Amer M., Corbin, John A., White, Mark L.

“…Many therapeutic antibodies act as antagonists to competitively block cellular signaling pathways. We describe here an approach for the therapeutic use of…”
Get full text

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia by Corbin, John A, Bhaskar, Vinay, Goldfine, Ira D, Issafras, Hassan, Bedinger, Daniel H, Lau, Angela, Michelson, Kristen, Gross, Lisa M, Maddux, Betty A, Kuan, Hua F, Tran, Catarina, Lao, Llewelyn, Handa, Masahisa, Watson, Susan R, Narasimha, Ajay J, Zhu, Shirley, Levy, Raphael, Webster, Lynn, Wijesuriya, Sujeewa D, Liu, Naichi, Wu, Xiaorong, Chemla-Vogel, David, Lee, Steve R, Wong, Steve, Wilcock, Diane, Rubin, Paul, White, Mark L

“…Novel therapies are needed for the treatment of hypoglycemia resulting from both endogenous and exogenous hyperinsulinema. To provide a potential new treatment…”
Get full text

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1b Activity by Roell, Marina K, Issafras, Hassan, Bauer, Robert J, Michelson, Kristen S, Mendoza, Nerissa, Vanegas, Sandra I, Gross, Lisa M, Larsen, Paul D, Bedinger, Daniel H, Bohmann, David J, Nonet, Genevieve H, Liu, Naichi, Lee, Steve R, Handa, Masahisa, Kantak, Seema S, Horwitz, Arnold H, Hunter, John J, Owyang, Alexander M, Mirza, Amer M, Corbin, John A, White, Mark L

“…Many therapeutic antibodies act as antagonists to competitively block cellular signaling pathways. We describe here an approach for the therapeutic use of…”
Get full text

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity by Roell, Marina K, Issafras, Hassan, Bauer, Robert J, Michelson, Kristen S, Mendoza, Nerissa, Vanegas, Sandra I, Gross, Lisa M, Larsen, Paul D, Bedinger, Daniel H, Bohmann, David J, Nonet, Genevieve H, Liu, Naichi, Lee, Steve R, Handa, Masahisa, Kantak, Seema S, Horwitz, Arnold H, Hunter, John J, Owyang, Alexander M, Mirza, Amer M, Corbin, John A, White, Mark L

“…Many therapeutic antibodies act as antagonists to competitively block cellular signaling pathways. We describe here an approach for the therapeutic use of…”
Get full text